Molecular Therapy — Methods & Clinical Development · 2019 · 29 citations · 25 references
Life SciencesBiochemistryMolecular BiologyGlycobiologyPost-translational ModificationProtein BiochemistryExtracellular Matrix GlycansGlycan BiosynthesisGlycan StructureGlycosylation PathwaysMuscular DystrophyProtein GlycosylationAdeno-associated Viral VectorsCeramide GlycosylationExtracellular Matrix ProteinsLaminin BindingMammalian Glycan BiosynthesisMuscle Fiber IntegrityMuscular Dystrophy PathophysiologyO-glycan Degradation
-mannosyl glycan on α-DG from substrate cytidine diphosphate (CDP)-ribitol, which is synthesized by isoprenoid synthase domain-containing protein (ISPD). We previously reported that oral administration of ribitol restores therapeutic levels of functional glycosylation of α-DG (F-α-DG) in a FKRP mutant mouse model. Here we examine the contribution of adeno-associated virus (AAV)-mediated overexpression of ISPD to the levels of CDP-ribitol and F-α-DG with and without ribitol supplementation in the disease model. ISPD overexpression alone and in combination with ribitol improves dystrophic phenotype. Furthermore, the combined approach of ribitol and ISPD acts synergistically, increasing F-α-DG up to 40% of normal levels in cardiac muscle and more than 20% in limb and diaphragm. The results suggest that low levels of substrate limit production of CDP-ribitol, and endogenous ISPD also becomes a limiting factor in the presence of a supraphysiological concentration of ribitol. Our data support further investigation of the regulatory pathway for enhancing efficacy of ribitol supplement to FKRP-related dystroglycanopathy.
25
Membrane organization of the dystrophin-glycoprotein complex
James M. Ervasti, Kevin P. Campbell · Cell · 1991 · 1.3K citations
Martin Brockington, Derek J. Blake, Paola Prandini et al. · The American Journal of Human Genetics · 2001 · 598 citations · Full text